SCHEMBL5508121

SCHEMBL5508121

N#Cc1ccc2oc(OC(=O)O)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
PLAU P00749 2/20 0.40
KMO O15229 1/20 0.39
PGR P06401 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
PIN1 Q13526 1/20 0.38
GPR35 Q9HC97 1/20 0.37
F2 P00734 2/20 0.37
PLG P00747 1/20 0.37
KLKB1 P03952 1/20 0.37
PRSS1 P07477 1/20 0.37
NCEH1 Q6PIU2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545814 0.78 FLT3 (0.54) MAOACA12CA9CA1CA2
SCHEMBL1819421 0.76 PIM1 (0.58) CYP2A6PLAUHRH3KDM4EALDH1A1
SCHEMBL5230393 0.76 CA12 (0.42) PLAUPGRCHRM2CHRM4CHRM5
SCHEMBL5163230 0.76 PIM1 (0.58) CYP2A6GPR35MAOACA12CA9
SCHEMBL3259550 0.76 KDM4E (0.54) GPR35CA12CA9CA1CA2
SCHEMBL30497735 0.76 CHEK2 (0.44) CYP2A6NOS3NOS1NOS2PLAU
SCHEMBL6240383 0.74 KDM4E (0.58) CYP2A6CA12CA9CA1CA2
SCHEMBL4200612 0.74 FLT3 (0.52) GPR35MAOACA12CA9CA1
SCHEMBL7384075 0.72 ALDH1A1 (0.61) CYP2A6NOS3NOS1NOS2PLAU
SCHEMBL8713424 0.72 HRH3 (0.48) CYP2A6NOS3NOS1NOS2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1519726-B1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-02-21 EP disclosed
EP-1749529-A1 Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases SCHWARZ PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1733727-A1 Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders SCHWARZ PHARMA AG (DE) 2006-12-20 EP disclosed
EP-1519726-A1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SCHWARZ PHARMA AG (DE) 2005-04-06 EP disclosed
WO-2004004729-A1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SCHWARZ PHARMA AG (DE) 2004-01-15 WO disclosed